Skip to main content
SpringerLink
Log in

Kognition bei Modellpsychosen

  • Chapter
Book cover Neuropsychologie der Schizophrenie

Auszug

Unter der Diagnose Schizophrenie werden Störungen mit unterschiedlichen Symptomen, stark variierendem Verlauf und funktionellem Outcome subsumiert. Vermutlich handelt es sich bei der Schizophrenie um eine Gruppe neurobiologisch heterogener Störungen mit lediglich überlappender Symptomatik und starken Fluktuationen in Abhängigkeit von Krankheitsstadium und Medikationsstatus. Als Ergebnis sind neurobiologische Befunde bei Patienten mit Schizophrenie — u. a. auch die hier interessierenden Befunde zu Kognition und Hirnaktivität — häufig inkonsistent und mit hohen Varianzen behaftet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 29.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43(11): 811–816

    Article  PubMed  CAS  Google Scholar 

  • Berckel BN van, Oranje B, Ree JM van, Verbaten MN, Kahn RS (1998) The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 137(3): 271–281

    Article  PubMed  Google Scholar 

  • Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17(10): 1497–1508

    Article  PubMed  Google Scholar 

  • Castner SA, Goldman-Rakic PS, Williams GV (2004) Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 174(1): 111–125

    Article  PubMed  CAS  Google Scholar 

  • Corlett PR, Honey GD, Aitken MR et al. (2006) Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry 63(6): 611–621

    Article  PubMed  Google Scholar 

  • D’Souza DC, Perry E, Macdougall L et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29(8): 1558–1572

    Article  PubMed  CAS  Google Scholar 

  • D’Souza DC, Abi-Saab WM, Madonick S et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57(6): 594–608

    Article  PubMed  CAS  Google Scholar 

  • Duncan EJ, Madonick SH, Parwani A et al. (2001) Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25(1): 72–83

    Article  PubMed  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Heekeren K, Thelen B et al. (1998a) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 9(7): 561–566

    Article  PubMed  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H (1998b) History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 39S: 263–268

    Google Scholar 

  • Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O et al. (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20(6): 565–581

    Article  PubMed  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Thelen B, Maier S et al. (2002) Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45(4): 205–212

    Article  PubMed  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Heekeren K, Neukirch A et al. (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38(6): 301–311

    Article  PubMed  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Heekeren K, Neukirch A et al. (2006) Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31(2): 431–441

    Article  PubMed  CAS  Google Scholar 

  • Heekeren K, Neukirch A, Daumann J et al. (2007) Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol 21(5): 312–320

    Article  PubMed  CAS  Google Scholar 

  • Hermle L, Funfgeld M, Oepen G et al. (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32(11): 976–991

    Article  PubMed  CAS  Google Scholar 

  • Honey RA, Honey GD, O’Loughlin C et al. (2004) Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology 29(6): 1203–1214

    Article  PubMed  CAS  Google Scholar 

  • Honey GD, Honey RA, O’Loughlin C et al. (2005a) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15(6): 749–759

    Article  PubMed  CAS  Google Scholar 

  • Honey GD, Honey RA, Sharar SR et al. (2005b) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology (Berl) 181(3): 445–457

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10): 1301–1308

    PubMed  CAS  Google Scholar 

  • Kreitschmann-Andermahr I, Rosburg T, Demme U, Gaser E, Nowak H, Sauer H (2001) Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res 12(1): 109–116

    Article  PubMed  CAS  Google Scholar 

  • Krystal JH, Karper LP, Seibyl JP et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3): 199–214

    PubMed  CAS  Google Scholar 

  • Krystal JH, Perry EB Jr, Gueorguieva R et al. (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62(9): 985–994

    Article  PubMed  CAS  Google Scholar 

  • Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13(1): 9–19

    Article  PubMed  CAS  Google Scholar 

  • Malhotra AK, Pinals DA, Weingartner H et al. (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14(5): 301–307

    Article  PubMed  CAS  Google Scholar 

  • Malhotra AK, Pinals DA, Adler CM et al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neurolepticfree schizophrenics. Neuropsychopharmacology 17(3): 141–150

    Article  PubMed  CAS  Google Scholar 

  • Morgan CJ, Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) 188(4): 408–424

    Article  PubMed  CAS  Google Scholar 

  • Oranje B, Berckel BN van, Kemner C, Ree JM van, Kahn RS, Verbaten MN (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22(3): 293–302

    Article  PubMed  CAS  Google Scholar 

  • Pechnick RN, Ungerleider JT (1997) Hallucinogens, In: Lowinson JH, Ruiz P, Millmon RB, Layrod JG (eds) Substance abuse — a comprehensive textbook. Williams & Wilkins, Baltimore, Md, pp 230–238

    Google Scholar 

  • Ranganathan M, D’Souza DC (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188(4): 425–444

    Article  PubMed  CAS  Google Scholar 

  • Riba J, Rodriguez-Fornells A, Barbanoj MJ (2002) Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology 165(1): 18–28

    Article  PubMed  CAS  Google Scholar 

  • Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM (2001) Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 25(4): 548–554

    Article  PubMed  CAS  Google Scholar 

  • Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57(12): 1139–1147

    Article  PubMed  CAS  Google Scholar 

  • Umbricht D, Koller R, Vollenweider FX, Schmid L (2002) Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 51(5): 400–406

    Article  PubMed  CAS  Google Scholar 

  • Umbricht D, Vollenweider FX, Schmid L et al. (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28(1): 170–181

    Article  PubMed  CAS  Google Scholar 

  • Vollenweider FX, Leenders KL, Scharfetter C (1997a) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7(1): 9–24

    Article  PubMed  CAS  Google Scholar 

  • Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997b) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16(5): 357–372

    Article  PubMed  CAS  Google Scholar 

  • Vollenweider FX, Csomor P, Knappe B, Geyer M, Quednow B (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology (in press). DOI 10.1038/sj.npp.1301324

    Google Scholar 

  • Wittmann M, Carter O, Hasler F et al. (2006) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21(1): 50–64

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universität zu Köln, Kerpener Str. 62, 50937, Köln

    E. Gouzoulis-Mayfrank (Prof. Dr. med.)

Authors
  1. E. Gouzoulis-Mayfrank
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Gouzoulis-Mayfrank, E. (2008). Kognition bei Modellpsychosen. In: Neuropsychologie der Schizophrenie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71147-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-71147-6_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-71146-9

  • Online ISBN: 978-3-540-71147-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation